• Empowering you with objective information to assess pulmonary nodules.

  • Potentially avoiding biopsy or surgery – a reason to smile.

  • Simultaneously measures multiple proteins associated with lung cancer.

Xpresys Lung

Xpresys Lung is a molecular blood test developed to provide non-invasive, objective information for assessment of pulmonary nodules. When combined with current clinical assessment, Xpresys Lung may be able to help reduce unnecessary invasive procedures. By reducing these, our objectives are to improve patient outcomes, reduce complications, and lessen the cost to the healthcare system.

Learn more

Latest News & Research

11/21/2016:
Integrated Diagnostics has completed the development of its second generation Xpresys Lung plasma proteomic molecular diagnostic. The development was based on two prospective trials enrolling over 1000 lung nodule patients from over 45 sites. The new test’s ability to rule out early stage cancer in lung nodules is very high in low to moderate risk patients with a 98% negative predictive value.

In order to prepare for the second generation Xpresys Lung test, commercial testing utilizing the first generation Xpresys Lung test has been halted. The Company anticipates offering the second generation Xpresys Lung after Medicare evaluation of the test and a successful coverage determination.

Read all news

Upcoming Events

View all events

About Indi

Indi is creating powerful new tools to help physicians diagnose complex diseases with a non-invasive blood test. By measuring multiple biomarkers that serve as sentinels of disease – we are creating tests that help physicians diagnose disease states with greater accuracy.

Learn more

Good Work
You are now leaving this website. If you would like to continue, click Continue.
Cancel Continue